Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Research

QD-Follicular-Lymphoma-WINTER
December 9, 2019/Cancer/Research

Lenalidomide/Monoclonal Antibody Combination Superior to PI3K Inhibitor Monotherapy as First Novel Agent in Relapsed Follicular Lymphoma

Study assesses outcomes of therapies with novel agents

T-cells_650x450
December 9, 2019/Cancer/Research

Findings Suggest CAR T-Cell Therapy is Highly Effective for Relapsed/Refractory Mantle Cell Lymphoma

Autologous anti-CD19 agent produces impressive survival improvements

QD-Myelofibrosis-GERDS
December 9, 2019/Cancer/Research

Treatment for Myelofibrosis-Associated Anemia on the Horizon

Interim results of phase 2 trial are promising

AML
December 8, 2019/Cancer/Research

Studies’ Results Support Liberalization of Some Eligibility Criteria for Acute Myeloid Leukemia Clinical Trials

Overly restrictive exclusions may lead to racial disparities and unrealistic outcomes

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Chemotherapy
December 7, 2019/Cancer/Research

Pediatric-inspired Post-remission Chemotherapy Superior to Stem Cell Transplantation for Young Adults with ALL

Study results from ASH 2019 shed light on treatment

650×450-Brain-Tumor2
September 19, 2019/Cancer/Research

Metabolic Reprogramming: A Promising Approach to Tackling Therapeutic Resistance in Glioblastoma

Targeting pyrimidine synthesis inhibits GSC self-renewal and tumorigenesis

650×450-Rectal-Cancer
September 18, 2019/Cancer/Research

Preoperative Pelvic Radiation is Safe, Effective in Patients with IBD and Rectal Cancer

Study affirms XRT’s utility

650×450-PSA-Test
September 17, 2019/Cancer/Research

Postprostatectomy Prostate-Specific Antigen Kinetics Associated with Recurrence After Salvage Radiation

Relapse more likely with faster PSA doubling time

human-b-lymphocyte from NIAID 650×450
September 4, 2019/Cancer/Research

Inotuzumab Ozogamicin Proves Superior to Standard Chemotherapy for Relapsed/Refractory ALL in a Long-Term Follow-up Study

Two-year follow-up confirms initial findings of the INO-VATE trial

650×350-Chemotherapy
August 15, 2019/Cancer/Research

Study Shows Survival Advantage for BEAM Conditioning Regimen in Hodgkin’s Lymphoma

Results prompt clinical practice change

BackPage 16 of 30Next

Advertisement

Ad